David Soergel - 15 May 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role: Chief Medical Officer
Signature: /s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol: MDGL
Transactions as of: 15 May 2025
Net transactions value: $0
Form type: 4
Filing time: 16 May 2025, 18:23:51 UTC
Previous filing: 24 Apr 2025
Next filing: 06 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Soergel David	Chief Medical Officer	C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN	/s/ Mardi Dier, as Attorney-in-Fact	16 May 2025	0001591475

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MDGL	Common Stock	Award	$0	+7,545		$0.000000	7,545	15 May 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MDGL	Stock Option (Right to Buy)	Award	$0	+12,839		$0.000000	12,839	15 May 2025	Common Stock	12,839	$291.82	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units, which vest as to 25% of the shares on each of May 15, 2026, May 15, 2027, May 15, 2028 and May 15, 2029, provided the Reporting Person continues in service with the Issuer on each such date.
F2	The option vests as to 25% of the shares on the first anniversary of the date of grant (May 15, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.